Angsuman Chakraborty01 Feb 2007 06:12 am
Singapore’s ES Cell International (ESI), a regenerative medicine company, and Scotland’s ITI Life Sciences, which funds early-stage research in life sciences, said they have signed a non-exclusive research license agreement that would allow ITI to take stem cell research to clinics.
The license announced Monday involves two British patents granted to Singapore-based ESI that cover aspects of human embryonic stem cell growth and differentiation, which are particularly important in clinical applications.
The deal is significant as it would add one more arrow to the United Kingdom’s stem cell quiver. The U.K. already has some of the most advanced policies in the world on stem cell research, funding both agencies and lab-to-clinic programs to perform such research.
Unlike the United States, where embryonic stem cell research is still a controversial, politically charged topic, stem cell research in the U.K. is a streamlined process. The U.K. has been ahead in formulating laws, setting up a stem cell lines bank, allocating funds, and allowing researchers to work with clinicians to take their research to clinics.
The entry of a Singapore company into the U.K. is significant as it will further add to the tools needed to take lab research to clinics.
ESI owns six of the 22 human embryonic stem (hES) cell lines currently listed on the U.S. National Institutes of Health (NIH) Stem Cell Registry, so it is in the forefront of developing basic technologies for doing hES research and developing applications.
Link [www.redherring.com/Article.aspx?a=21012&hed=Stem+Cell+Firm+Licenses+Patents§or=Industries&subsector=Biosciences]
Filed under Stem Cell | Comment Below
Related?
Stem cell production at commercial level gets a green signalJuly 17th, 2009 Madison stem cell firm Cellular Dynamics International Inc. said Wednesday it has licensed a pair of patents that will advance its effort to mass produce stem cell-derived cells for pharmaceutical companies.
Stem-Cell Patents to be Reviewed by the Federal GovernmentOctober 7th, 2006 The federal government will re-examine three stem-cell patents held by the Wisconsin Alumni Research Foundation, a move that could threaten WARF's financial windfall from the research and Madison's prominence in the field. The patents, based on work by UW-Madison scientist James Thomson, are controlled by WARF, the university's nonprofit technology transfer arm.
Stem Cell Isolating Method To Get EU PatentJune 23rd, 2006 Ortec International said Tuesday (20th June) the European patent office has granted the firm a patent on its Fibrin Microbead technology for isolating certain types of adult stem cells. The technology has previously been granted five U.S.
UW embryonic stem cell patent right for PfizerMay 6th, 2009 The Wisconsin Alumni Research Foundation claimed that have provides Pfizer the rights to work with human embryonic stem cells for drug research and discovery. Renowned pharmaceutical company Pfizer Inc.
Russian clinics and beauty salons peddling stem cell therapyApril 14th, 2005 While the rest of the world is cautiously experimenting with stem cell therapy, Russian clinics and beauty salons have claimed that they are already using both adult and embryonic stem cells to treat everything from wrinkles to Parkinson's disease to impotence. Scientists warn that while stem cells are still being researched in laboratories, treatment by clinics claiming to use stem cells may cost patients their health and fortunes.
You May Donate Unused Embryos for Stem Cell Research April 2nd, 2007 There are almost half-million frozen embryos stored in fertility clinic freezers across the country. Most couples attempting to have children through in-vitro fertilization keep their unused frozen embryos indefinitely.
U.S. Patents may encourage Novocell to initiate more groundbreaking stem cell research September 18th, 2008 Renowned Stem cell engineering company Novocell,Inc., yesterday announced that the U.S. Patent and Trademark Office has issued two patents related to its stem cell encapsulation technology and granted Notice of Allowance for a patent relating to the Company’s technology for the isolation of clinical-grade human embryonic stem cell (hESC) lines.
Stem Cell Studies Moving To Clinics in IndiaApril 19th, 2006 At present, the stem cell research is moving from labs to clinics in India as sufficient pre-clinical data are being generated to take up clinical application, says Dr C M Habibullah, director, Centre for Liver Diseases and dean, Deccan College of Medicine at Hyderabad, while speaking at the Third All India Conference on Regenerative Medicine and Tissue Engineering. Presently, stem cell research and clinical application is goin on in ophthalmology, liver diseases, dermatology, neural regeneration and cardiology and peripheral vascular diseases.
Leave a Comment
